Analyzing CLSE's Impressive Performance and Future Prospects
Finance

Analyzing CLSE's Impressive Performance and Future Prospects

authorBy Mariana Mazzucato
DateAug 01, 2026
Read time2 min
This article provides an in-depth analysis and update on the Convergence Long/Short Equity ETF (CLSE), a fund employing an active long/short equity strategy. It reiterates a positive outlook, highlighting the fund's impressive outperformance against key market benchmarks and discussing the factors contributing to its success, as well as potential considerations for investors.

Unlocking Alpha: A Deep Dive into CLSE's Strategic Investment Approach

Convergence Long/Short Equity ETF: Strategy and Recent Performance

The Convergence Long/Short Equity ETF (CLSE) employs an active management strategy designed to generate alpha through a net long portfolio. This approach has consistently piqued my interest, prompting regular updates on its performance.

Reaffirming a 'Buy' Rating: CLSE's Proven Adaptability

My confidence in CLSE's strategy remains strong, leading me to reaffirm a 'Buy' rating. This stance is bolstered by its notable outperformance, exceeding 11% since my last review in February, a clear indicator of its robust adaptability in varying market conditions.

Impressive Annualized Active Return Since ETF Conversion

Since its transformation into an ETF, CLSE has achieved an impressive annualized active return of 7.15%, using IWV as its benchmark. This performance is particularly significant given that it was achieved with a lower standard deviation, suggesting efficient risk management.

Outperforming Benchmarks: A Consistent Trend

Despite a slight dip in performance during July, CLSE has maintained a substantial lead over IVV, IWV, and QQQ year-to-date. This consistent outperformance strengthens my expectation that CLSE will continue to surpass IVV's returns well into 2027.

Key Considerations for Investors: Risks and Expense Ratio

While CLSE's performance is compelling, investors should carefully evaluate the inherent risks. These include the complexities and potential volatility associated with short selling, a core component of its strategy, as well as its relatively high expense ratio, which can impact overall returns.

More Articles
Finance
Top Retirement Cities for Food Enthusiasts
For retirees who enjoy dining out, this article identifies top retirement destinations that boast thriving restaurant scenes and community amenities. It highlights major culinary cities, unique gastronomic locales, and smaller towns with emerging food cultures, offering diverse options for retirees based on their budget, lifestyle preferences, and desired dining experiences.
By Suze OrmanAug 01, 2026
Finance
Weekly Dividend Activities of Leading Companies
This article provides a weekly analysis of dividend activities for companies featured in the Dividend Champions, Contenders, and Challengers lists. It highlights firms that have adjusted their dividend payouts, along with those having upcoming ex-dividend and pay dates. The goal is to offer investors timely updates beyond the monthly Champion list releases, ensuring they stay informed about critical dividend-related changes.
By Michele FerreroAug 01, 2026
Finance
Strategic Enhancements to an Income-Focused Investment Portfolio
This article discusses the strategic addition of Capital One Financial Preferred Series N and McDonald's to an income-focused investment portfolio. The author emphasizes securing reliable, qualified dividend income, with a focus on dividend safety, yield, and potential for capital appreciation. The rationale behind each addition is detailed, highlighting Capital One's high, well-covered yield and McDonald's dividend reliability and growth potential after a recent price dip, reflecting a conservative yet growth-oriented investment approach.
By Michele FerreroAug 01, 2026
Finance
uniQure Faces Regulatory Hurdles for Huntington's Disease Treatment
uniQure N.V. has been downgraded from a Strong Buy rating to Hold due to mounting regulatory uncertainties surrounding its experimental drug, AMT-130, for Huntington's Disease. Despite the FDA reversing its initial stance to allow an accelerated approval pathway, requiring a confirmatory Phase 3 trial, significant challenges remain. The company plans to submit its Biologics License Application (BLA) in Q3 2026, coinciding with the release of four-year Phase 1/2 data, with a similar filing targeted for the UK. While uniQure boasts substantial cash reserves expected to fund operations until 2030, a more cautious outlook is advised until key regulatory milestones are achieved.
By Suze OrmanJul 31, 2026
Finance
Navigating Mortgage Debt in Retirement: A Comprehensive Analysis
This article explores the prevalence and implications of carrying mortgage debt into retirement, drawing on Federal Reserve data. It reveals that a significant portion of older adults, including those well into their 70s and 80s, still have outstanding housing loans. The piece delves into the reasons behind this trend, the financial impact on retirees, and offers insights for strategic retirement planning.
By Fareed ZakariaJul 31, 2026